[Paper-level Aggregated] PMCID: PMC9900321

Evidence Type(s): Oncogenic

Summary: Mutation: Gly-to-Asp | Summary: The Gly-to-Asp mutation (KRASG12D) is prevalent in pancreatic ductal adenocarcinoma and contributes to tumor development and progression, as evidenced by its high occurrence in patients with this cancer type.

Gene→Variant (gene-first): KRAS(3845):Gly-to-Asp

Genes: KRAS(3845)

Variants: Gly-to-Asp

[Paper-level Aggregated] PMCID: PMC9900321

Evidence Type(s): Predictive

Summary: Mutation: Gly-to-Asp | Summary: The Gly-to-Asp mutation (KRASG12D) is associated with the efficacy of the small-molecule KRASG12D inhibitor, MRTX1133, indicating a correlation with treatment response in pancreatic ductal adenocarcinoma models.

Gene→Variant (gene-first): KRAS(3845):Gly-to-Asp

Genes: KRAS(3845)

Variants: Gly-to-Asp

[Paragraph-level] PMCID: PMC9900321 Section: ABSTRACT PassageIndex: 3

Evidence Type(s): Predictive, Oncogenic

Summary: Evidence Type: Predictive | Mutation: Gly-to-Asp | Summary: The Gly-to-Asp mutation (KRASG12D) is associated with the efficacy of the small-molecule KRASG12D inhibitor, MRTX1133, indicating a correlation with treatment response in pancreatic ductal adenocarcinoma models. Evidence Type: Oncogenic | Mutation: Gly-to-Asp | Summary: The Gly-to-Asp mutation (KRASG12D) is prevalent in pancreatic ductal adenocarcinoma and contributes to tumor development and progression, as evidenced by its high occurrence in patients with this cancer type.

Gene→Variant (gene-first): 3845:Gly-to-Asp

Genes: 3845

Variants: Gly-to-Asp

[Paper-level Aggregated] PMCID: PMC9900321

Evidence Type(s): Oncogenic, Predictive

Justification: Oncogenic: The passage indicates that Gly-to-Asp mutations (KRASG12D) are commonly found in pancreatic ductal adenocarcinoma (PDAC), suggesting that this variant is associated with the development of cancer. Predictive: The text discusses the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in models with KRASG12D mutations, indicating that the presence of this variant can predict the response to targeted therapy.

Gene→Variant (gene-first): KRAS(3845):Gly-to-Asp

Genes: KRAS(3845)

Variants: Gly-to-Asp

[Paragraph-level] PMCID: PMC9900321 Section: ABSTRACT PassageIndex: 3

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in treating pancreatic ductal adenocarcinoma, indicating a correlation between the Gly-to-Asp mutation and response to therapy. Oncogenic: The Gly-to-Asp mutation in the KRAS oncogene is described as contributing to tumor development in pancreatic ductal adenocarcinoma, as it is found in more than 90% of patients with this cancer type.

Gene→Variant (gene-first): 3845:Gly-to-Asp

Genes: 3845

Variants: Gly-to-Asp

[Paragraph-level] PMCID: PMC9900321 Section: ABSTRACT PassageIndex: 3

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in treating pancreatic ductal adenocarcinoma, indicating a correlation between the Gly-to-Asp mutation and response to therapy. Oncogenic: The Gly-to-Asp mutation in the KRAS oncogene is described as contributing to tumor development in pancreatic ductal adenocarcinoma, as it is found in more than 90% of patients with this cancer type.

Gene→Variant (gene-first): 3845:Gly-to-Asp

Genes: 3845

Variants: Gly-to-Asp